At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Our solution for continuous tableting lines is ConsiGma®, a 6 sigma-inspired manufacturing platform, incorporating different technologies to produce oral solid dosage forms in a continuous, cost-efficient way:
Showing 4 of 8
The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.
An indispensable part of the ConsiGma 4.0 portfolio, the Conductor 4.0 control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line
A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.
Designed to achieve optimal blending results, the ConsiGma® DB modules facilitate the testing of dosing and blending operations and can be integrated with any continuous up- or downstream process.
GEA's innovative process marks a milestone in the pretreatment of biofuels such as hydro-treated vegetable oil and sustainable aviation fuel. By eliminating the bleaching process, manufacturers benefit from significant savings potential: over 50% lower operating costs and up to 12% less CO2 emissions.
Climate change and a growing world population put increased pressure on the energy-intensive food industry to feed more people without further impacting the planet. George Shepherd, GEA’s Global Technical Sustainability Manager, explains how GEA uses its engineering know-how to help processors produce more sustainably yet increase productivity.